Janus Henderson Group PLC Grows Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Janus Henderson Group PLC increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 2,397.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 377,384 shares of the company’s stock after acquiring an additional 362,276 shares during the period. Janus Henderson Group PLC owned approximately 0.58% of Kymera Therapeutics worth $15,197,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KYMR. Wellington Management Group LLP boosted its position in shares of Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after buying an additional 688,967 shares during the period. Avoro Capital Advisors LLC raised its stake in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $23,856,000. Boxer Capital Management LLC bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $17,098,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock valued at $276,395,000 after acquiring an additional 224,859 shares in the last quarter.

Insider Activity

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock valued at $324,567 over the last ninety days. 16.01% of the stock is currently owned by insiders.

Kymera Therapeutics Trading Up 0.8%

Shares of KYMR stock opened at $30.25 on Friday. The business’s fifty day simple moving average is $29.36 and its 200-day simple moving average is $37.05. The company has a market cap of $1.97 billion, a PE ratio of -12.93 and a beta of 2.18. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s quarterly revenue was up 114.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.69) earnings per share. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price target for the company. Guggenheim reaffirmed a “buy” rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday, May 12th. UBS Group decreased their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Stephens reissued an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.27.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.